• Why is the Neometals (ASX:NMT) share price in a trading halt today?

    A business man holds his hand out in a stop sign, indicating a share price trading halt or company in trouble

    The Neometals Ltd (ASX: NMT) share price is not going anywhere today after a trading halt was placed on the company’s shares. The Neometals share price has spent the last few days, and months for that matter, climbing enthusiastically.

    Yesterday, Neometals was up almost 9% to a new 52-week high of 56 cents a share. Year to date, the company is up more than 90%, and over the past 12 months, 250%.

    Neometals is an ASX lithium exploration company. The company owns a refinery project in India. In addition, Neometals owns recycling operations that extract lithium and vanadium from batteries and steel slag.

    So what happened this morning?

    Well, the company put out an ASX release requesting a training halt for its shares, that’s what. This happened at 9:54 am, just before market open.

    So, here’s what Neometals had to say when it requested the trading halt:

    Neometals Ltd (Company) requests that ASX grant an immediate trading halt with respect to the Company’s securities pending an announcement regarding an update on study results for the Company’s Battery Recycling project. The Company requests that the trading halt remain in place until the earlier of commencement of trading on Monday, 10 May 2021 or the time the Company makes an announcement.

    The “company’s battery recycling project” could refer to Neometals‘ announcement on 5 March. This flagged a memorandum of understanding between ‘Primobius GmbH’ (a joint venture between Neometals and SMS Group GmbH) and Japan’s Itochu Corporation. This memorandum of understanding (MoU) “provides a framework towards establishing a corporation for battery recycling” between the two parties.

    According to the ASX announcement, the two parties have commenced planning discussions and preparations for a “dedicated demonstration plant trial”. It also announced that “it is intended that future binding legal agreements will encapsulate sales of recycled product to establish a circular economy for Itochu based on the use of Primobius recycling technology”. The plant trial is scheduled to begin operations in the 3 months to June 30 2021.

    What else has been affecting the Neometals share price?

    It was only last month that Neometals shares were in a spot of bother over plans for the company to initiate a dual listing. The company announced on 23 April that it plans to list on the London Stock Exchange. The listing will take place in the first half of FY2022. This sent Neometals shares down 1% at the time.

    At the current (albeit frozen) share price of 56 cents, Neometals has a market capitalisation of $302.5 million.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Why is the Neometals (ASX:NMT) share price in a trading halt today? appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3h4MfiT

  • Why the GUD (ASX:GUD) share price is pushing higher today.

    hand on touch screen lit up by a share price chart moving higher

    In morning trade the GUD Holdings Limited (ASX: GUD) share price is pushing higher.

    At the time of writing, the diversified products company’s shares are up 1% to $13.34.

    Why is the GUD share price pushing higher?

    Investors have been buying the company’s shares following the release of a trading update after the market close on Wednesday.

    According to the release, the company’s performance during the third quarter has been in line with expectations.

    The Automotive business has experienced strong workshop end user demand, which has underpinned year to date organic sales growth of 15%.

    Management also revealed that it could be adding to the business in the near future. It advised that there is no shortage of aftermarket acquisition opportunities. Though, it will maintain its disciplined approach, with adherence to clearly defined acquisition and pricing criteria.

    Things aren’t quite as positive for the Water business. Its year to date organic sales are up 4% over the prior corresponding period. However, management notes that COVID lockdown impacts are continuing as production ramps to meet a sales backlog with associated incremental costs.

    This includes shift penalties, outwards/export air freight, partial factory closure, which are impacting margins. Positively, though, management advised that the company has a strong inventory position to support demand.

    One concern for investors, which is likely to be holding back the GUD share price a touch today, is that its cost inflation is slightly above levels flagged with its first half results. This is being driven by freight costs and supplier price rise requests, which are under negotiation

    Despite this, management has positively narrowed its FY 2021 underlying earnings before interest and tax (EBIT) guidance to $98 million to $100 million. This compares to its previous guidance of $95 million to $100 million. The company has also retained its cash conversion target of ~80% to 85%.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Why the GUD (ASX:GUD) share price is pushing higher today. appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3b5ffDi

  • Nearmap (ASX:NEA) share price dives 16% on legal proceedings

    nervous looking asx investor holding hands to her face

    Nearmap Ltd (ASX: NEA) shares surged almost 15% on Wednesday after the company upgraded its FY21 guidance. However, its shares then went into a trading halt before market close in relation to potential legal proceedings. 

    Today, the Nearmap share price is plunging after the company acknowledged the legal proceedings filed on behalf of competing aerial imagery firm, Eagle View Technologies and its subsidiary Pictometry International Corp. 

    Legal proceedings drive Nearmap share price lower 

    The Nearmap share price is currently trading 16.31% lower at $1.975 following the company’s update on the legal proceedings. The announcement reveals that Eagle View Technologies and Pictometry International Corp have filed a complaint against Nearmap’s subsidiary, Nearmap US, in the United States District Court. 

    The complaint alleges patent infringement in relation to Eagle View’s roof estimation technology. Nearmap believes that the allegations do not affect its core proprietary technology and do not affect the survey of imagery or the delivery of premium content. 

    Nearmap CEO and Managing Director Dr Rob Newman commented on the matter, saying: 

    Nearmap has always taken the subject of intellectual property rights and patent protections seriously and believes the allegations are without merit. We will vigorously defend against the complaint. The business remains unaffected by the complaint.

    Eagle View’s patent infringement complaint 

    The complaint filed to the Utah courts highlights that: 

    Plaintiffs EagleView and Pictometry now bring this action to halt Nearmap’s infringement of eight (8) patents, and obtain other relief as necessary.

    The complaint states that “Nearmap has and continues to directly infringe and/or indirectly infringe, by way of inducement, the ’152, ’880, ’518, ’961, ’737, ’568, ’960, and ’149 Patents” 

    For example, the 152 patient, entitled “Concurrent Display Systems and Methods for Aerial Roof Estimation” was issued by the United States Patent and Trademark Office on 26 June 2012. The complaint alleges that: 

    Nearmap’s product is remarkably similar to, and appears to have been copied from, EagleView’s technology and roof reports, confirming that Nearmap monitors EagleView’s website, products, roof reports, and patents.

    Foolish takeaway

    Following today’s falls, the Nearmap share price is now trading 13% lower year to date. The company’s shares have, however, gained almost 19% since this time last year. Nearmap has a market capitalisation of around $1 billion.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nearmap Ltd. The Motley Fool Australia has recommended Nearmap Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Nearmap (ASX:NEA) share price dives 16% on legal proceedings appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3xRT0KE

  • Is the ANZ (ASX:ANZ) share price a buy following its half year results?

    A teacher in front of a classroom chalkboard filled with questionmarks, indicating share market uncertainty

    On Thursday morning, the Australia and New Zealand Banking GrpLtd (ASX: ANZ) share price is edging lower.

    At the time of writing, the banking giant’s shares are down 0.5% to $27.77.

    This means the ANZ share price is now down 3.5% since the release of its half year results.

    Is the weakness in the ANZ share price a buying opportunity for investors?

    According to a note out of Goldman Sachs, its analysts believe the ANZ share price is in the buy zone.

    In response to its half year results, the broker has retained its buy rating and increased its price target to $30.20.

    This price target implies potential upside of approximately 9% over the next 12 months excluding dividends.

    And if you include the 5% fully franked dividend yield that Goldman Sachs is forecasting, this potential return stretches to 14%.

    What did the broker say?

    Goldman gave its verdict on ANZ’s half year result.

    It stated: “ANZ’s 1H21 cash earnings grew 112% on pcp to A$2,990 mn, with the beat largely driven by a lower than expected BDD charge. 1H21 PPOP came in 3% lower than GSe, driven by trading and fee income, partially offset by better NIMs and expenses. The proposed interim DPS of A70¢ implies a payout ratio of 67% (DRP to be neutralised) and 1H21 CET1 ratio of 12.4% (18.1% globally-harmonised), 44 bp stronger than GSe.”

    Why is Goldman Sachs bullish?

    Goldman Sachs is positive on the ANZ share price due to its valuation and cost reduction plans. It expects the latter to offset income pressures.

    The broker said: “We maintain our Buy rating on ANZ given our expectation that cost reductions, if achieved, will more than offset income pressures, while valuations remain supportive.”

    “To this end, we note that i) ANZ’s NIM is being very effectively managed in the face of weaker volumes; a trend we expect to continue through FY21E, ii) the resulting revenue pressures, which are also being adversely impacted by fees (and Markets in 1H21), should be offset by productivity benefits in outer years, iii) the stock is trading more than one standard deviation cheap versus the sector on PPOP multiples (24% discount vs. 11% long-run average discount), despite our expectations that it will deliver 5% PPOP/share CAGR in the two years to FY23E (with upside from capital management), with a c. 5% dividend yield; and iv) our TP offers c. 13% TSR [now ~14%],” it concluded.

    Despite this recent weakness, the ANZ share price is up 20% year to date.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Is the ANZ (ASX:ANZ) share price a buy following its half year results? appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/33ktJLi

  • Why the Zelira (ASX:ZLD) share price is storming 7% higher

    ASX Cannabis share price represented by asx investor holding card with cannabis leaf on it

    The Zelira Therapeutics Ltd (ASX: ZLD) share price is firmly in the green today following a positive update for its HOPE products.

    At the time of writing, the cannabis company’s shares are swapping hands for 5.7 cents, up 7.55%.

    What did Zelira announce?

    Investors appear upbeat by the company’s latest announcement, sending the Zelira share price higher.

    According to this morning’s release, Zelira advised its HOPE products have launched in Washington DC. Additionally, Zelira noted that this occurred through its partnership with Alternative Solutions. 

    Alternative Solutions is a licenced grower, manufacturer, and distributor of medical cannabis products. The company operates in the District of Columbia (Washington DC), United States.

    Furthermore, both companies entered into an exclusive licence agreement in late 2020 to expand the market presence for Zelira’s range of HOPE products.

    Currently, Washington DC has an agreement with 32 other states within the country for approved medical cannabis programs. The mutual exchange allows patients who are registered in the authorised states to legally buy medical cannabis in Washington DC.

    Zelira stated that HOPE is available at the National Holistic Healing Centre, located near Dupont Circle.

    As part of the deal, Zelira will receive an upfront fee and ongoing royalties from product sales within Washington DC. The company did not provide any further details regarding the financial aspects of the contract.

    In addition, Zelira holds a licencing agreement with Ilera Healthcare LLC and Advanced Biomedics LLC for Pennsylvania and Louisiana, respectively. Management believes that customer adoption and sales will be similar in Washington DC and other markets.

    Management commentary

    Zelira managing director, Dr Oludare Odumosu hailed the company’s success, saying:

    The successful launch of HOPE in Washington DC is a huge step forward in Zelira’s strategic focus on expanding access to HOPE throughout the USA. We look forward to partnering with Alternative Solutions to support the growth of our product in these new markets.

    Alternative Solutions CEO, Matt Lawson-Baker further commented:

    We are thrilled to partner with Zelira in bringing HOPE to Washington DC and look forward to bringing patients scientifically formulated medicines they can trust.

    Zelira share price snapshot

    Since the beginning of 2021, investors have seen the Zelira share price continue to fall in value. Year-to-date performance stands at a loss of more than 40%, reflecting weak shareholder sentiment.

    Based on current valuations, Zelira presides a market capitalisation of around $63 million, with close to 1.2 billion shares outstanding.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Why the Zelira (ASX:ZLD) share price is storming 7% higher appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3hch4ls

  • Starpharma (ASX:SPL) share price surges higher on COVID product update

    A woman kicks a giant COVID-19 molecule, indicating positive share price movement for biotech companies

    The Starpharma Holdings Limited (ASX: SPL) share price has been a strong performer on Thursday.

    At the time of writing, the dendrimer products developer’s shares are up 6% to $1.89.

    Why is the Starpharma share price racing higher?

    Investors have been buying Starpharma’s shares following the release of an update on its Viraleze antiviral nasal spray.

    According to the release, the Viraleze antiviral nasal spray is now available for purchase by consumers in Europe via the company’s webstore.

    This follows the recent launch of Viraleze in the United Kingdom through LloydsPharmacy’s 1,400 stores and online business. It is also expected to be available via independent United Kingdom pharmacies later this month.

    What is Viraleze?

    Viraleze is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013). This is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute.

    These antiviral studies were conducted at the renowned Scripps Research Institute in the United States and a number of other specialist virology laboratories.

    It isn’t just multiple strains of COVID-19 that Viraleze has been demonstrated to have potent antiviral activity. It also has been found to have potent antiviral activity against RSV (respiratory syncytial virus), MERS, and SARS.

    Management notes that the antiviral active in Viraleze works by irreversibly blocking coronavirus SARS-CoV-2 ‘spike’ proteins from binding to human airway cells. This forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages. One of these is its ability to inactivate the virus either before or after exposure.

    Starpharma’s CEO, Dr Jackie Fairley, commented: “We are delighted to be rolling out Viraleze in Europe following the UK launch. The product has been very well received in the UK, and we hope that Viraleze will provide European consumers with added peace of mind.”

    “In addition to making Viraleze available direct to consumers in Europe via www.viraleze.co, commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in Viraleze,” she concluded.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Starpharma (ASX:SPL) share price surges higher on COVID product update appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uACrAM

  • Why the Appen (ASX:APX) share price is down 6% to a multi-year low

    appen share price

    The Appen Ltd (ASX: APX) share price is sinking lower on Thursday morning.

    In morning trade, the artificial intelligence (AI) data services company’s shares are down 6% to a multi-year low of $13.82.

    Why is the Appen share price sinking?

    Investors have been selling the company’s shares this morning following the release of a presentation ahead of its appearance at the Macquarie Group Ltd (ASX: MQG) conference.

    While that presentation didn’t include any new financial data, the company’s CEO, Mark Brayan, provided a lot of colour of industry conditions.

    Mr Brayan started by explaining why market conditions have been choppy during COVID-19, which has impacted demand, its growth, and ultimately the Appen share price.

    He said: “Clearly, ours is a dynamic market. Our customers, large and small, are responding to market forces, including those above, and developing AI products at speed, to better their competitors.”

    “Coupled with this is the fact that AI product development is experimental. The performance of the underlying model is unknown until it’s built and tested in the real world. This results in an iterative process in which models are built, tested, tuned, re-tested and so on. Training data is an essential component of machine learning and is tied to our customers’ product development lifecycles. As such, training data volume requirements are not always linear.”

    “This is the primary reason behind the recent choppiness in our growth. Our major customers are reprioritising their product development projects as they iterate and build new products in response to dynamic market forces. This has resulted in changing data volumes on a handful of large projects and this impacted our revenue,” Mr Brayan explained.

    Current trading conditions

    Positively, he advised that there’s been no change in the need for training data. More companies are investing in AI and they all need training data.

    Mr Brayan notes that the high growth in the number of customers it is winning, including in China, is a testament to this.

    The CEO also revealed that the competitive environment for relevance data is unchanged, with Appen and Lionbridge AI remaining the key providers. Relevance represents ~90% of its revenue, so this is a big positive.

    Pleasingly, the company is not seeing any unusual pressure on pricing. Mr Brayan advised that its “customers want a good deal and they negotiate well, but they will pay for quality and reliability and our reputation is strong in these areas.”

    What else did Appen say?

    While the above was positive, there were a few items that appear to be the reason why the Appen share price is falling today.

    Mr Brayan explained: “Our customers are developing new AI products in response to COVID’s impact on online advertising last year and regulatory pressures such as anti-trust and data privacy. This dictates the data they need for product development and impacts their engineering resource allocations and the volumes and types of data they need from us.”

    “As stated before, machine learning is an iterative process, and our customers are switching resources between development projects as they pursue new break-out products. This in turn has impacted a handful of our larger programs.”

    “Our competitors outside of relevance are maturing. This is unsurprising. Their presence and funding demonstrate that ours is an attractive market. We maintain our leadership position and our customers rely on us for quality, scale, security and reliability but it means that we have to maintain our flow of new product features and fight harder to stay ahead,” he added.

    The company is aiming to offset this by looking beyond data collection and labelling for additional growth paths in the broader AI market. Management expects that these will be technical in nature and build on its products, customer base, and market position.

    The Appen share price is now down 46% year to date.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Appen Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Why the Appen (ASX:APX) share price is down 6% to a multi-year low appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/33mbK70

  • Adore Beauty (ASX:ABY) share price plunges 10% on quarterly update

    falling asx share price represented by woman making sad face

    The Adore Beauty Group Ltd (ASX: ABY) share price is plummeting after the company released a third-quarter trading update this morning. In early trade, the beauty e-tailer’s shares are trading 9.83% lower at $4.13.

    Let’s take a look at how the company has been performing.

    Third-quarter highlights 

    According to Adore Beauty, third-quarter trading has remained strong, with revenue up 47% on the prior corresponding period to $39.4 million. This was driven by solid customer retention and re-engagement rates for new customers acquired during the COVID-19 lockdown period. A strong performance came out of core categories including skincare and hair care. 

    The update also confirmed the company’s FY21 revenue growth range of 43% to 47%, an uplift from its pre-COVID revenue growth of 38.6% in FY19. 

    Adore Beauty CEO Tennealle O’Shannessy commented on the results, saying: 

    The business is making strong progress on our strategy to leverage our online market leadership to further capture market share in a large and growing market. We continue to make disciplined investments in our mobile app, loyalty program, content capabilities, range and adjacency expansion opportunities and private label development. We look forward to updating investors further at our inaugural full year result presentation in August

    The ‘significant opportunity’ for Adore Beauty 

    Adore Beauty has highlighted the significant online opportunity at hand within the beauty and personal care (BPC) market in Australia. The company estimates that the BPC market in Australia is worth approximately $11.2 billion with an expected compound annual growth rate (CAGR) of 26% to 2024. 

    Online sales currently comprise 11.4% of the BPC market in Australia, a lower penetration rate than in more developed markets such as the United Kingdom, United States and China. As a pure-play online beauty retailer, the company believes there is a significant opportunity at hand to capitalise on the structural shift towards online retail.

    Adore Beauty’s strategy remains focused on growing its market share through investments to drive brand awareness, new customer acquisition and returning customer retention. 

    Adore Beauty share price struggles since listing 

    The Adore Beauty share price is significantly lower than its listing price of $6.75 and debut price of $7.42. Adore Beauty listed during a period when several other initial public offerings (IPOs) also struggled to make headway after listing. These included ASX shares such as Zebit Inc (ASX: ZBT), MyDeal.com.au Pty Ltd (ASX: MYD) and CleanSpace Holdings Ltd (ASX: CSX), all of which slumped lower after listing. 

    Another headwind facing Adore Beauty shares has been the recent weakness across ASX e-commerce shares. E-commerce peers including Kogan.com Ltd (ASX: KGN) and Redbubble Ltd (ASX: RBL) have been slammed in recent weeks following a period of tough comparables against supercharged FY20 figures driven by pandemic lockdowns.

    While Adore Beauty has reported solid year-on-year growth figures, its shares are arguably swimming against the tide as the broader e-commerce sector is sold down. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Adore Beauty Group Limited. The Motley Fool Australia has recommended CleanSpace Holdings Limited and Kogan.com ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Adore Beauty (ASX:ABY) share price plunges 10% on quarterly update appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3tlFqf9

  • Has Mastercard’s stock gone too far, too fast?

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    woman using Mastercard

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    There are few companies in the world tied to consumers’ financial health the way Mastercard (NYSE: MA) is. It processes an incredible $6.3 trillion worth of transactions each year and therefore can be really sensitive to economic shocks that result in less consumer spending. The COVID-19 pandemic was probably as significant a shock as Mastercard could expect to see, but looking back, the company didn’t perform too badly.

    With a market capitalization of $372 billion at Wednesday’s prices, Mastercard’s stock trades near all-time highs. However, its recent gains owe more to multiple expansion than earnings growth. Right now, the stock trades at a significant 58 times trailing-12-month earnings. That’s a little skewed because of the effects of the pandemic — but the stock is richly priced based on expected earnings for 2022, too. If you’re a Mastercard investor, what should you make of this valuation?

    The everything business

    Investors are clearly willing to pay higher valuations for Mastercard as time progresses, and perhaps one of the reasons is because it has never been truly disrupted. The reality is, it’s integrated with almost every bank in the world, and they have issued over 2.8 billion of the company’s cards to consumers as of December 2020. It will be extremely difficult for new entrants to unseat such a dominant position, although new direct payment technologies like “Buy Now, Pay Later” are giving it a shot. Ultimately, the main competitor it has is Visa

    Year

    Total Mastercard Payment Volume

    2017

    $5.2 trillion

    2018

    $5.9 trillion

    2019

    $6.5 trillion

    2020

    $6.3 trillion

    Data source: Company filings.

    Gross payment volume was growing nicely until the pandemic struck, although the effects were probably a lot smaller than expected in the early moments of 2020. Payment volume has returned to growth, though, with the first-quarter 2021 earnings report showing $1.7 trillion, up 8% compared to the same time last year. If that level remains consistent throughout the year, Mastercard stands to grow compared to both 2020 and its peak in 2019.

    Emerging financial technology companies like Affirm have tried to bypass both Mastercard and the big banks, integrating directly with online merchants to facilitate payments (plus providing financing to customers). While very popular with consumers, this model so far has failed to generate meaningful profits, and some players — like Australian company ZipPay — have even partnered with Mastercard to deliver ”digital credit cards” for their customers. So even as disruptors enter the payments scene, it turns out they greatly benefit from Mastercard’s services and become customers as much as competitors. 

    Truly global

    The U.S. makes up just 31% of Mastercard’s total net income — it’s a truly global business. Over $4.3 billion of the company’s $6.4 billion is derived worldwide, so it puts the effects of the pandemic into perspective. For the full year 2020, Mastercard’s cross-border transaction volume declined by a significant 29%, as less consumers could travel on account of border closures around the world.

    In the first quarter of 2021, the company reported cross-border volumes down 17%, which is an improvement but still markedly suppressed. The issue going forward is whether consumers will be able to move around the world during the U.S. and European summer — and more importantly, whether they actually want to. Vaccination programs are ramping up, but countries like Italy are still under substantive lockdowns domestically and are only just preparing to welcome tourists later in May.

    With no opportunity to prepare or plan summer holidays, it remains to be seen if popular destinations will attract tourists, which would really impact Mastercard’s ability to climb out of the cross-border volume crater left by COVID-19. Losing another summer could really stifle Mastercard’s hopes for an earnings rebound. 

    The bottom line

    Mastercard has been consistently trading at an earnings multiple near 40, which is understandable given the powerful growth rate in earnings per share

    Calendar Year

    Earnings Per Share (Fully Diluted)

    Share Price*

    Multiple*

    2017

    $3.65

    $168.70

    46.2

    2018

    $5.60

    $211.05

    37.7

    2019

    $7.94

    $316.50

    39.9

    2020

    $6.37

    $316.55

    49.7

    As of May 5, 2021

     

    $375.00

    57.7 (2020 earnings)

    2021

    $7.92 (estimate)

    $375.00

    47.3

    2022

    $10.44 (estimate)

    $375.00

    35.9

    Data source: Calculated by author using company filings. *Share price and multiple captured on Jan. 31 following the respective full-year earnings reports. Estimated 2021 and 2022 earnings from Yahoo! Finance.

    Looking at 2021 and 2022 estimates, the company seems fairly valued for the next two years unless it manages to blow out analyst expectations. This leaves some risk to the downside if it fails to meet them, so investors might be considering their risk versus reward when buying the stock at these levels. 

    Mastercard’s not the only payments provider with a slightly rich valuation, and this is likely the effect of ultra-low interest rates buoying the entire sector as the cost of money remains suppressed. 

    Visa trades at 48 times earnings for the past 12 months, and 37 times consensus estimates for the next 12 months. Visa is a bit bigger than Mastercard, with a roughly $508 billion market cap and $11.6 trillion in gross transaction volume in 2019 (pre-COVID), with 3.4 billion cards issued. However, the companies operate very similar business models.

    American Express, while in the same business as Visa and Mastercard, operates with a very different model. It issues cards directly to consumers rather than solely to third parties, and it also provides credit products. While still a large company at $125 billion, it attracts a lower current earnings multiple of 25 times trailing earnings and just 23 times forward estimates. The market typically attributes higher risk to finance companies, as they could pose significant downside during an adverse credit event. 

    Looking ahead

    Considering the historical valuation of Mastercard, and the fact that it seems close to fully valued through 2022 (assuming earnings estimates prove accurate), investors may want to think about the potential upside versus the opportunity cost of putting money elsewhere. While interest rates are low, which has boosted consumer spending, they could rise as the broader economy heats up.

    For the company to deliver meaningful share price growth over the next two years, it might need to materially beat analyst expectations on earnings, through organic growth or increased market share. Without that, the stock could stagnate, and investors would need to be patient.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Mastercard and Visa. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of ZIPCOLTD FPO. The Motley Fool Australia has recommended Mastercard. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post Has Mastercard’s stock gone too far, too fast? appeared first on The Motley Fool Australia.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    from The Motley Fool Australia https://ift.tt/3xR8azJ

  • These could be the next up and coming ASX lithium shares

    Cut outs of cogs and machinery with chemical symbol for lithium

    Galaxy Resources Ltd (ASX: GXY), Orocobre Ltd (ASX: ORE) and Pilbara Minerals Ltd (ASX: PLS) dominate the lithium scene on the ASX. However, there are a number of small cap ASX lithium shares with big plans to begin production in the near term. 

    The next up and coming ASX lithium shares 

    Core Lithium Ltd (ASX: CXO) 

    Core Lithium is in the advanced exploration stages for its Finniss Lithium project. The company is continuing its drilling campaigns to increase mineral resources, mine life, and project revenues. Core Lithium is also targeting the completion of an optimised definitive feasibility study in 2Q21. This will be conducted ahead of a final investment decision followed by plant construction. 

    On 5 May, the company announced a major lithium exploration and resource drilling push at Finniss. Core Lithium managing director Stephen Biggins said: 

    We are about to launch the largest exploration and resource drilling campaigns in the Company’s history with the aspiration of more than doubling Core’s Lithium Resources and Finniss Project’s Life of Mine.

    From an offtake perspective, the company has secured a number of agreements. Furthermore, these agreements account for approximately 85% of its first three years of annual spodumene production. More recently, the company also announced that its largest shareholder and key Tesla supplier, Yahua, had planned to double its lithium hydroxide output

    Piedmont Lithium Ltd (ASX: PLL) 

    Piedmont follows a similar timeline as Core Lithium. However, a number of exploration updates are required before the final financing and construction phases. 

    For the remainder of the calendar year, the company expects to deliver additional mineral resource updates. In addition, it will deliver an integrated scoping study update and an integrated definitive feasibility study. Should everything go to plan, the company should be eyeing the construction of its integrated project by the beginning of 2022.

    Piedmont is well funded for its upcoming updates with a recent successful listing on the US market. This bolstered the company’s cash position to $167 million for the March quarter. 

    Where to invest $1,000 right now

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

    *Returns as of February 15th 2021

    More reading

    Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

    The post These could be the next up and coming ASX lithium shares appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3xOfe08